Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.9209238352912 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
NASDAQ:ACHN traded up $0.08 on Thursday, reaching $3.68. The stock had a trading volume of 286,094 shares, compared to its average volume of 2,042,168. The firm has a market cap of $490.90, a PE ratio of -5.92 and a beta of 0.89. Achillion Pharmaceuticals has a 1-year low of $2.58 and a 1-year high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the business posted ($0.03) EPS. analysts expect that Achillion Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.